Related Experiment Videos
[Therapy for systemic urothelial cancer recurrence]
1Klinik für Urologie und Kinderurologie, Universitätsklinikum des Saarlandes, Homburg/Saar. jan.lehmann@uniklinikum-saarland.de
Der Urologe. Ausg. A
|March 9, 2005
Summary
Treating urothelial cancer recurrences after surgery is challenging due to limited data. This review covers chemotherapy trials, metastasectomy, and other therapies for systemic urothelial cancer, aiding treatment decisions.
Area of Science:
- Oncology
- Urologic Oncology
- Cancer Research
Context:
- Limited data exists for treating systemic urothelial cancer recurrences post-surgery.
- Radical cystectomy and upper tract surgery are common treatments for urothelial cancer.
- Systemic recurrences pose significant challenges in patient management.
Purpose:
- To review available data on managing systemic urothelial cancer recurrences.
- To discuss therapeutic options including chemotherapy, metastasectomy, radiotherapy, and targeted therapy.
- To provide an overview of current treatment strategies for advanced urothelial cancer.
Summary:
- This review analyzes data from two Phase III trials on systemic chemotherapy for metastatic/inoperable urothelial cancer and adjuvant chemotherapy post-cystectomy.
- It also examines contemporary series on metastasectomy for urothelial cancer with palliative and curative intent.
- The discussion encompasses radiotherapy, surgery, conventional chemotherapy, and targeted therapy for systemic recurrences.
Impact:
- This review aims to inform clinical decision-making for urothelial cancer recurrences.
- It highlights the need for more data on managing advanced urothelial cancer.
- Understanding treatment impacts can improve outcomes for patients with metastatic or recurrent urothelial cancer.